HOMA-IR Insulin Resistance Calculator

Understanding Insulin Resistance Through HOMA-IR

Insulin resistance occurs when cells in muscle, fat, and liver respond poorly to insulin and cannot easily absorb glucose from blood. To compensate, the pancreas produces extra insulin. This state precedes type 2 diabetes by years and contributes to metabolic syndrome, cardiovascular disease, polycystic ovary syndrome (PCOS), and non-alcoholic fatty liver disease (NAFLD).

HOMA-IR quantifies this relationship using fasting glucose and insulin levels. The formula is: HOMA-IR = (fasting insulin μIU/mL × fasting glucose mmol/L) / 22.5. If you have glucose in mg/dL, divide by 18.018 to convert to mmol/L. For example, with fasting glucose 100 mg/dL (5.55 mmol/L) and insulin 12 μIU/mL: HOMA-IR = (12 × 5.55) / 22.5 = 2.96, indicating insulin resistance.

This calculation reflects the interplay between glucose and insulin: in insulin-resistant states, both glucose and insulin tend to be elevated fasting, producing high HOMA-IR scores. Conversely, insulin-sensitive individuals maintain low fasting glucose with minimal insulin, yielding low HOMA-IR. The model provides a snapshot of how hard your pancreas works to maintain glucose homeostasis.

HOMA-Beta and Pancreatic Function

While HOMA-IR measures insulin resistance, HOMA-Beta assesses beta-cell function—the pancreas's capacity to secrete insulin. The formula is: HOMA-Beta = (20 × fasting insulin μIU/mL) / (fasting glucose mmol/L - 3.5). Normal beta-cell function is set at approximately 100%, with values varying around this baseline.

In early insulin resistance, HOMA-Beta often exceeds 100-150% as beta cells work overtime to compensate for reduced insulin sensitivity. This hyperinsulinemia maintains normal glucose but places stress on the pancreas. Over years, beta cells can exhaust, and HOMA-Beta declines below 50%, signaling inadequate insulin production and progression toward diabetes.

The combination of HOMA-IR and HOMA-Beta provides a metabolic profile. High HOMA-IR with high HOMA-Beta suggests compensated insulin resistance. High HOMA-IR with low HOMA-Beta indicates decompensated resistance with failing beta-cell reserve—the critical transition point where prediabetes becomes diabetes. Longitudinal tracking shows how interventions like weight loss and exercise improve both parameters.

Clinical Applications and Limitations

HOMA-IR is widely used in research to stratify metabolic risk and track intervention effects. Clinically, it helps identify insulin resistance in patients with normal glucose, guiding early lifestyle interventions before prediabetes develops. Women with PCOS often show elevated HOMA-IR, informing treatment with insulin sensitizers like metformin. NAFLD severity correlates with HOMA-IR, useful for monitoring liver disease progression.

Limitations include variability in insulin assays between laboratories, which can affect cutoff values. Fasting state must be strictly maintained; even small carbohydrate intake invalidates results. HOMA works best in the non-diabetic range; once diabetes develops, the model's assumptions break down. It provides a single-point estimate, whereas direct measures like glucose clamp studies or continuous glucose monitoring offer dynamic insulin sensitivity assessment.

Despite these limitations, HOMA-IR remains the most practical tool for large-scale screening and routine practice. Improving HOMA-IR through lifestyle changes—losing 5-10% body weight, exercising regularly, reducing refined carbohydrates, increasing fiber—reduces diabetes risk and reverses metabolic syndrome features. Serial measurements every 3-6 months during interventions provide objective feedback on metabolic improvement, motivating sustained behavior change and guiding pharmacotherapy decisions.